Sun Pharmaceutical Industries Limited (Sun Pharma) today announced LEQSELVI™ (deuruxolitinib) is now commercially available for the treatment of severe alopecia areata in adults. This marks the third FDA-approved treatment on the market for severe disease. “The availability of LEQSELVI offers hope to our community, delivering a new, effective treatment option for adults living with severe alopecia areata,” said Nicole Friedland, President and CEO, National Alopecia Areata Foundation (NAAF). “NAAF is thrilled to see expanded choices and increased opportunities for individuals to find an FDA-approved treatment to address hair loss caused by this autoimmune disease.” LEQSELVI™ belongs to a class of medications known as Janus kinase (JAK) inhibitors. It is available by prescription only in 8 mg tablets. Read Sun Pharma’s press release here. Learn more: Read about FDA-approved JAK inhibitor treatments for alopecia areata. Read more at LEQSELVI.com.
